Inhibrx Croissance future
Future contrôle des critères 2/6
Inhibrx is forecast to grow earnings and revenue by 9.1% and 59.7% per annum respectively while EPS is expected to grow by 13.1% per annum.
Informations clés
9.1%
Taux de croissance des bénéfices
13.1%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 27.1% |
| Taux de croissance des recettes | 59.7% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 13 May 2024 |
Mises à jour récentes de la croissance future
Pas de mise à jour
Recent updates
Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 122 | -296 | N/A | N/A | 1 |
| 12/31/2025 | 2 | -361 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -316 | N/A | N/A | 2 |
| 3/31/2024 | 2 | -271 | -222 | -216 | N/A |
| 12/31/2023 | 2 | -241 | -198 | -193 | N/A |
| 9/30/2023 | 0 | -189 | -169 | -167 | N/A |
| 6/30/2023 | 1 | -172 | -144 | -144 | N/A |
| 3/31/2023 | 1 | -163 | -129 | -128 | N/A |
| 12/31/2022 | 2 | -145 | -116 | -115 | N/A |
| 9/30/2022 | 5 | -125 | -108 | -107 | N/A |
| 6/30/2022 | 7 | -111 | -91 | -90 | N/A |
| 3/31/2022 | 7 | -94 | -87 | -86 | N/A |
| 12/31/2021 | 7 | -82 | -81 | -80 | N/A |
| 9/30/2021 | 7 | -78 | -74 | -73 | N/A |
| 6/30/2021 | 11 | -78 | -75 | -73 | N/A |
| 3/31/2021 | 13 | -75 | -64 | -62 | N/A |
| 12/31/2020 | 13 | -76 | -49 | -48 | N/A |
| 9/30/2020 | 10 | -75 | -46 | -45 | N/A |
| 6/30/2020 | 6 | -74 | -33 | -31 | N/A |
| 3/31/2020 | 6 | -68 | -36 | -34 | N/A |
| 12/31/2019 | 13 | -51 | -34 | -32 | N/A |
| 9/30/2019 | 15 | -40 | -29 | -27 | N/A |
| 6/30/2019 | 15 | -30 | -29 | -27 | N/A |
| 3/31/2019 | 14 | -26 | -28 | -27 | N/A |
| 12/31/2018 | 9 | -31 | -25 | -23 | N/A |
| 9/30/2018 | 7 | -35 | -24 | -23 | N/A |
| 12/31/2017 | 8 | -19 | N/A | -19 | N/A |
| 12/31/2016 | 7 | -8 | N/A | -18 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: INBX.V is forecast to remain unprofitable over the next 3 years.
Bénéfices vs marché: INBX.V is forecast to remain unprofitable over the next 3 years.
Croissance élevée des bénéfices: INBX.V is forecast to remain unprofitable over the next 3 years.
Chiffre d'affaires vs marché: INBX.V's revenue (59.7% per year) is forecast to grow faster than the US market (8.5% per year).
Croissance élevée des revenus: INBX.V's revenue (59.7% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if INBX.V's Return on Equity is forecast to be high in 3 years time